Clinical Trial Detail

NCT ID NCT02779751
Title A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Eli Lilly and Company
Indications

Her2-receptor negative breast cancer

non-small cell lung carcinoma

Therapies

Abemaciclib + Pembrolizumab

Age Groups: adult

Additional content available in CKB BOOST